Updates are available Correction dated 2021-04-01
Click to view Correction: https://doi.org/10.1186/s13024-021-00446-3
-
Authors
Cummings, Jeffrey https://orcid.org/0000-0001-8944-4158
-
Funding
Funding for this research was provided by:
National Institute of General Medical Sciences (P20GM109025)
National Institute of Neurological Disorders and Stroke (U01NS093334)
National Institute on Aging (R01AG053798)
- License Information
-
More Information
Article History
Received: 26 August 2020
Accepted: 2 January 2021
First Online: 13 January 2021
Change Date: 1 April 2021
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1186/s13024-021-00446-3
Ethics approval and consent to participate
: Not applicable.
: Not applicable.
: JC has provided consultation to Acadia, Actinogen, AgeneBio, Alkahest, Alzheon, Annovis, Avanir, Axsome, Biogen, Cassava, Cerecin, Cerevel, Cortexyme, Cytox, EIP Pharma, Eisai, Foresight, GemVax, Genentech, Green Valley, Grifols, Karuna, Merck, Novo Nordisk, Otsuka, Resverlogix, Roche, Samumed, Samus, Signant Health, Suven, and United Neuroscience pharmaceutical and assessment companies. Dr. Cummings has stock options in ADAMAS, AnnovisBio, MedAvante, BiOasis. Dr. Cummings owns the copyright of the Neuropsychiatric Inventory.
